@article {DI PIERRO4201, author = {GIOVANNI BATTISTA DI PIERRO and PIETRO GRANDE and LIVIO MORDASINI and HANSJ{\"O}RG DANUSER and AGOSTINO MATTEI}, title = {Safety and Efficacy of Robot-assisted Radical Prostatectomy in a Low-volume Center: A 6-year Single-surgeon Experience}, volume = {36}, number = {8}, pages = {4201--4207}, year = {2016}, publisher = {International Institute of Anticancer Research}, abstract = {Aim: To analyze safety and efficacy of robot-assisted radical prostatectomy (RARP) in a low-volume centre. Patients and Methods: From 2008 to 2015, 400 consecutive patients undergoing RARP were prospectively enrolled. Complications were classified according to the Modified Clavien System. Biochemical recurrence (BCR) was defined as two consecutive prostate-specific antigen (PSA) values >=0.2 ng/ml. Functional outcomess were assessed using validated, self-administered questionnaires. Results: Median patient age was 64.5 years. Mean standard deviation (SD) preoperative PSA level was 11.3 (11.7) ng/ml. Median interquartile range (IQR) follow-up was 36 (12-48) months. Overall complication rate was 27.7\% (minor complications rate 16.2\%). Overall 1-, 3- and 6-year BCR-free survival rates were 85.7\%, 77.5\% and 53.9\%, respectively; these rates were 94.1\%, 86.2\% and 70.1\% in pT2 diseases. At follow-up, 98.4\% of patients were fully continent (median (IQR) time to continence was 2 (1-3) months) and 68.2\% were potent (median (IQR) time to potency of 3 (3-4) months). Conclusion: RARP appears to be a valuable option for treating clinically localised prostate cancer also in a low-volume institution.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/36/8/4201}, eprint = {https://ar.iiarjournals.org/content/36/8/4201.full.pdf}, journal = {Anticancer Research} }